Viosera
DefunctFounded 2016 · 2 known investors
Viosera Therapeutics is a biotechnology company founded to develop resistance-proof antimicrobial drugs.
Also known as Viosera · Viosera Therapeutics
Investors · 2
Company profile
researched Aug 2026Viosera Therapeutics is a biotechnology venture focused on developing antimicrobial drugs designed to be resistance-proof, meaning therapies intended to remain effective as target pathogens evolve.
The company was founded by Nicholas Goldner, PhD, Christopher Bulow, PhD, and Gautam Dantas, a professor of pathology and immunology, biomedical engineering, microbiology, and pediatrics. Two of its founders subsequently went on to start resistanceBio, a company addressing drug resistance in cancer that participated in Y Combinator's Winter 2019 batch and was based in San Francisco; that successor company is listed as inactive.
Founding story
Viosera Therapeutics was established by Nicholas Goldner, PhD, Christopher Bulow, PhD, and academic researcher Gautam Dantas, with the stated purpose of developing antimicrobial drugs that would not be undermined by the emergence of drug resistance. Goldner holds a PhD in molecular cell biology with a research focus on how living cells survive in hostile environments, and Bulow has since worked in core technologies at Arcadia Science. Both Goldner and Bulow later co-founded resistanceBio, applying a related resistance-focused approach to oncology; Goldner served as its CEO and co-founder.
▸Full profile — market position, technology, go-to-market
Market position
Viosera Therapeutics operates in antimicrobial therapeutics, a segment of drug development concerned with countering microbial drug resistance. Its founding team spans academic microbiology and molecular cell biology research.
Technology
The company's stated technical focus is the development of antimicrobial drugs intended to be resistance-proof, addressing the tendency of microbial pathogens to evolve tolerance to existing antibiotics.
Go-to-market
As a therapeutics developer, the company's work is directed at antimicrobial drug development for infectious disease treatment.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 1
launches, deals, and filingsFounders Christopher Bulow and Nicholas Goldner shifted focus from antibiotic resistance to cancer, resulting in the spin-out of resistanceBio in early 2021.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- Viosera Therapeutics Founders: Nicholas Goldner, PhD & Christopher Bulow, PhD | FounderTracefoundertrace.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Viosera do?
- Viosera Therapeutics is a biotechnology company founded to develop resistance-proof antimicrobial drugs.
- Who are Viosera's investors?
- Viosera's investors include Brightstone Venture Capital, Dreamers VC.